Sarepta Therapeutics (SRPT) Stock Price, Quote & News

Company Profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dy...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 274 4000

Website: www.sarepta.com

Address:

215 First Street, Suite 415, Cambridge, United States

c319419 Jun. 24 at 1:50 AM

$SRPT This will not run until/unless they release some sort of positive news, thus why the analyst downgraded it today saying there are no near term positive catalysts. I will be a buyer again, but not right now.

0 · Reply

Mendoza_333 Jun. 24 at 12:47 AM

$SRPT run tomorrow or 18.32?

0 · Reply

Qutiaw Jun. 24 at 12:35 AM

$SRPT

0 · Reply

JX35 Jun. 24 at 12:32 AM

$SRPT can SRPT pull a RETA? $226-$19- $166? Let’s see what Roche pays out

0 · Reply

JX35 Jun. 24 at 12:23 AM

$SRPT from $160 to $20 what’s Roche waiting on?

0 · Reply

JustRightTime Jun. 24 at 12:21 AM

$SRPT It's going up tomorrow.

0 · Reply

ElonMusk101 Jun. 24 at 12:11 AM

$SRPT $19.49 ah…back over $20 tomorrow

0 · Reply

Gregorythetraderguy Jun. 23 at 11:47 PM

$SRPT so under 18.50 tomorrow on my way to being in the money? Yeah baby yeah

0 · Reply

TradeVestor Jun. 23 at 11:44 PM

$SRPT "Just" $22 this week would be wild.

0 · Reply

Cpak Jun. 23 at 10:52 PM

$SRPT this should pump tomorrow

0 · Reply

Analyst Downgrades Sarepta As Elevidys Safety Clouds Future Demand

Jun 20, 2025, 9:08 AM EDT - 3 days ago

SRPT INQUIRY: Sarepta Therapeutics, Inc. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law (NASDAQ:SRPT)

Jun 18, 2025, 8:38 AM EDT - 5 days ago

SRPT NOTICE: Did Sarepta Therapeutics, Inc. Mislead Investors about the Safety of Elevidys? Contact BFA Law if You Lost Money (NASDAQ:SRPT)

Jun 17, 2025, 8:07 AM EDT - 6 days ago

SRPT BREAKING NEWS: Sarepta Therapeutics, Inc. is being Investigated for Securities Fraud after Second Elevidys Death; Investors with Losses are Notified to Contact BFA Law

Jun 17, 2025, 7:40 AM EDT - 6 days ago

SRPT Stock: What's Happening With Sarepta Therapeutics?

Jun 16, 2025, 6:16 PM EDT - 7 days ago

Mizuho's Jared Holz on what is next for Sarepta after second death connected to gene therapy

Jun 16, 2025, 12:14 PM EDT - 7 days ago

Down To Levels Not Seen Since 2016: Initiating Sarepta With A Buy

Jun 16, 2025, 11:11 AM EDT - 7 days ago

Sarepta's gene therapy medicine kills patient, CEO suspends full year guidance

Jun 16, 2025, 10:30 AM EDT - 7 days ago

SRPT Down Near 9-Year Low, CSCO Upgrade, ROKU Using AMZN Ads

AMZN CSCO ROKU

Jun 16, 2025, 9:00 AM EDT - 7 days ago

Sarepta Therapeutics' Elevidys Liver Deaths Trigger Selloff, A Contrarian Opportunity

Jun 16, 2025, 8:38 AM EDT - 7 days ago

Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session

KULR

Jun 16, 2025, 6:18 AM EDT - 7 days ago

Sarepta Stock Crashes After Death of Second Patient Receiving Its Gene Therapy

Jun 16, 2025, 5:01 AM EDT - 7 days ago

Sarepta shares tumble on second patient death after gene therapy treatment

Jun 16, 2025, 1:57 AM EDT - 7 days ago

Sarepta Therapeutics: Rebuilding The Thesis After Hitting Rock Bottom

Jun 15, 2025, 2:06 AM EDT - 8 days ago

Sarepta reports second case of liver failure death after its gene therapy treatment

Jun 15, 2025, 1:00 AM EDT - 8 days ago

Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne

Jun 4, 2025, 9:30 AM EDT - 19 days ago

U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta's Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4

May 21, 2025, 8:30 AM EDT - 4 weeks ago

Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy

May 16, 2025, 9:01 AM EDT - 5 weeks ago

Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment

May 16, 2025, 9:00 AM EDT - 5 weeks ago

Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2

May 13, 2025, 9:25 AM EDT - 5 weeks ago

Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy

May 9, 2025, 7:16 AM EDT - 6 weeks ago

Top 3 Health Care Stocks That Are Preparing To Pump This Quarter

PRTA RXST

May 8, 2025, 4:30 PM EDT - 6 weeks ago

Sarepta Therapeutics to Present at the BofA Securities Health Care Conference

May 7, 2025, 2:14 PM EDT - 6 weeks ago

Sarepta: ELEVIDYS DMD Treatment Setback Brings Downgrade To Hold Rating

May 7, 2025, 1:07 PM EDT - 6 weeks ago

Sarepta Therapeutics Stock Sinks On Gloomy Forecast, Analysts Expect Demand To Pick Up

May 7, 2025, 12:14 PM EDT - 6 weeks ago

Sarepta Therapeutics: Lowered Elevidys Guidance Warrant Ratings Downgrade

May 7, 2025, 11:13 AM EDT - 6 weeks ago

New vaccine chief rocks pharmaceutical stocks

BNTX MRNA NVAX PFE GSK IBB XBI

May 7, 2025, 9:28 AM EDT - 6 weeks ago

Sarepta Therapeutics Analysts Slash Their Forecasts After Q1 Results

May 7, 2025, 8:10 AM EDT - 6 weeks ago

Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

ANET MRCY

May 6, 2025, 10:41 PM EDT - 6 weeks ago

Sarepta Therapeutics, Inc. (SRPT) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:05 PM EDT - 6 weeks ago

Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments

May 5, 2025, 9:00 AM EDT - 7 weeks ago

SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Apr 22, 2025, 8:30 AM EDT - 2 months ago

Sarepta Therapeutics to Announce First Quarter 2025 Financial Results

Apr 15, 2025, 8:30 AM EDT - 2 months ago

Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs

Apr 4, 2025, 8:55 AM EDT - 2 months ago

Sarepta halts three studies testing gene therapy for muscle disorder

Apr 4, 2025, 8:44 AM EDT - 2 months ago

Sarepta Therapeutics Provides Update on ELEVIDYS

Apr 3, 2025, 3:23 PM EDT - 2 months ago

Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death

Apr 3, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Therapeutics, Inc. (SRPT) And Encourages Shareholders to Connect

Apr 2, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sarepta Therapeutics, Inc. (SRPT) And Encourages Shareholders to Reach Out

Apr 1, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Shareholders to Learn More About the Investigation

Mar 31, 2025, 5:54 PM EDT - 3 months ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 31, 2025, 2:25 PM EDT - 3 months ago

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul

BNTX NVAX SLDB TSHA XBI

Mar 31, 2025, 10:00 AM EDT - 3 months ago

Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Mar 30, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Investors to Learn More About the Investigation

c319419 Jun. 24 at 1:50 AM

0 · Reply

Mendoza_333 Jun. 24 at 12:47 AM

$SRPT run tomorrow or 18.32?

0 · Reply

Qutiaw Jun. 24 at 12:35 AM

$SRPT

0 · Reply

JX35 Jun. 24 at 12:32 AM

$SRPT can SRPT pull a RETA? $226-$19- $166? Let’s see what Roche pays out

0 · Reply

JX35 Jun. 24 at 12:23 AM

$SRPT from $160 to $20 what’s Roche waiting on?

0 · Reply

JustRightTime Jun. 24 at 12:21 AM

$SRPT It's going up tomorrow.

0 · Reply

ElonMusk101 Jun. 24 at 12:11 AM

$SRPT $19.49 ah…back over $20 tomorrow

0 · Reply

Gregorythetraderguy Jun. 23 at 11:47 PM

$SRPT so under 18.50 tomorrow on my way to being in the money? Yeah baby yeah

0 · Reply

TradeVestor Jun. 23 at 11:44 PM

$SRPT "Just" $22 this week would be wild.

0 · Reply

Cpak Jun. 23 at 10:52 PM

$SRPT this should pump tomorrow

0 · Reply

Gregorythetraderguy Jun. 23 at 10:44 PM

$SRPT pumpers here be pumpy

0 · Reply

Gregorythetraderguy Jun. 23 at 10:43 PM

$SRPT plz don’t hammer my shausage

0 · Reply

Gregorythetraderguy Jun. 23 at 9:44 PM

$SRPT Bring the hammer !!!!

0 · Reply

Deekay1 Jun. 23 at 9:29 PM

$SRPT Looks like she wants to hit double bottom before any legit move up...

1 · Reply

Gregorythetraderguy Jun. 23 at 9:17 PM

$SRPT Welp this positive news after hours sure isn’t doing anything to hurt my puts lol I am the put daddy

0 · Reply

Researchmonster11 Jun. 23 at 8:56 PM

$SRPT good stage three clinical trials. https://www.cgtlive.com/view/sarepta-therapeutics-limb-girdle-muscular-dystrophy-gene-therapy-srp-9003-safety-5-year-data

0 · Reply

Researchmonster11 Jun. 23 at 8:52 PM

$SRPT EMERGENE info coming out soon. https://musculardystrophynews.com/news/fda-oks-trial-srp-9005-gene-therapy-lgmd-type-2c/

0 · Reply

EpicEric Jun. 23 at 8:47 PM

$SRPT well, that was a scary 15 mins into the close - huge spike in volume! But there's a buyer for every seller...who are they - that's the question...

1 · Reply

EpicEric Jun. 23 at 8:41 PM

$SRPT seriously, this is a tad too much... This idiot made a paper profit of a couple of bucks and can't stop gloating.. Blocked

0 · Reply

Gregorythetraderguy Jun. 23 at 8:30 PM

$SRPT longs…what makes you think this is the bottom? Genuinely curious….

1 · Reply

Gregorythetraderguy Jun. 23 at 8:24 PM

$SRPT will this do another stair step down for my puts tomorrow?

0 · Reply

TooHot_toTouch Jun. 23 at 8:23 PM

$CAPR $SRPT $CPIX At the end of the day, these companies are all fighting to survive and advance within the system not against each other. The price actions in each should be a good lesson to all - Keep that in mind when you feel the need to gloat on the other board(s). And I will always keep Doug responsible for not trying to buy CAPR for $ 2B when SRPT was over $ 15B (Missed opportunity for sure.)

0 · Reply

Market Cap	1.97B
Revenue (ttm)	1.90B
Net Income (ttm)	235.24M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	12.37%
Debt to Equity Ratio	1.00

Volume	6,930,900
Avg Vol	5,335,202
Day's Range	N/A - N/A
Shares Out	98.28M
Stochastic %K	3%
Beta	0.61
Analysts	Sell
Price Target	$52.43